First-in-Human trial tests new shot for genetic lung and liver disease
NCT ID NCT07431112
Summary
This is a first-step study to see if a new injected medicine called AIR-001 is safe and how it behaves in the body of people with Alpha-1 Antitrypsin Deficiency (AATD). It will enroll 54 adults with a specific genetic form (PiZZ) of the disease. The main goal is to check for side effects and measure how much of the drug gets into the bloodstream.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Study Center
RECRUITINGMelbourne, Australia
-
Clinical Study Center
RECRUITINGLondon, United Kingdom
Conditions
Explore the condition pages connected to this study.